161 related articles for article (PubMed ID: 14737110)
1. MYCN-mediated regulation of the MRP1 promoter in human neuroblastoma.
Manohar CF; Bray JA; Salwen HR; Madafiglio J; Cheng A; Flemming C; Marshall GM; Norris MD; Haber M; Cohn SL
Oncogene; 2004 Jan; 23(3):753-62. PubMed ID: 14737110
[TBL] [Abstract][Full Text] [Related]
2. MYCN enhances P-gp/MDR1 gene expression in the human metastatic neuroblastoma IGR-N-91 model.
Blanc E; Goldschneider D; Ferrandis E; Barrois M; Le Roux G; Leonce S; Douc-Rasy S; Bénard J; Raguénez G
Am J Pathol; 2003 Jul; 163(1):321-31. PubMed ID: 12819037
[TBL] [Abstract][Full Text] [Related]
3. Bmi1 is a MYCN target gene that regulates tumorigenesis through repression of KIF1Bbeta and TSLC1 in neuroblastoma.
Ochiai H; Takenobu H; Nakagawa A; Yamaguchi Y; Kimura M; Ohira M; Okimoto Y; Fujimura Y; Koseki H; Kohno Y; Nakagawara A; Kamijo T
Oncogene; 2010 May; 29(18):2681-90. PubMed ID: 20190806
[TBL] [Abstract][Full Text] [Related]
4. Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features.
Tajiri T; Liu X; Thompson PM; Tanaka S; Suita S; Zhao H; Maris JM; Prendergast GC; Hogarty MD
Clin Cancer Res; 2003 Aug; 9(9):3345-55. PubMed ID: 12960121
[TBL] [Abstract][Full Text] [Related]
5. MYCN-regulated miRNA-92 inhibits secretion of the tumor suppressor DICKKOPF-3 (DKK3) in neuroblastoma.
Haug BH; Henriksen JR; Buechner J; Geerts D; Tømte E; Kogner P; Martinsson T; Flægstad T; Sveinbjørnsson B; Einvik C
Carcinogenesis; 2011 Jul; 32(7):1005-12. PubMed ID: 21572098
[TBL] [Abstract][Full Text] [Related]
6. CTCF cooperates with noncoding RNA MYCNOS to promote neuroblastoma progression through facilitating MYCN expression.
Zhao X; Li D; Pu J; Mei H; Yang D; Xiang X; Qu H; Huang K; Zheng L; Tong Q
Oncogene; 2016 Jul; 35(27):3565-76. PubMed ID: 26549029
[TBL] [Abstract][Full Text] [Related]
7. Minichromosome maintenance protein MCM7 is a direct target of the MYCN transcription factor in neuroblastoma.
Shohet JM; Hicks MJ; Plon SE; Burlingame SM; Stuart S; Chen SY; Brenner MK; Nuchtern JG
Cancer Res; 2002 Feb; 62(4):1123-8. PubMed ID: 11861392
[TBL] [Abstract][Full Text] [Related]
8. Targeted MYCN expression affects cytotoxic potential of chemotherapeutic drugs in neuroblastoma cells.
Paffhausen T; Schwab M; Westermann F
Cancer Lett; 2007 May; 250(1):17-24. PubMed ID: 17141950
[TBL] [Abstract][Full Text] [Related]
9. Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma.
Haber M; Smith J; Bordow SB; Flemming C; Cohn SL; London WB; Marshall GM; Norris MD
J Clin Oncol; 2006 Apr; 24(10):1546-53. PubMed ID: 16575006
[TBL] [Abstract][Full Text] [Related]
10. Importance of Sp1 consensus motifs in the MYCN promoter.
Inge TH; Casson LK; Priebe W; Trent JO; Georgeson KE; Miller DM; Bates PJ
Surgery; 2002 Aug; 132(2):232-8. PubMed ID: 12219017
[TBL] [Abstract][Full Text] [Related]
11. The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma.
Slack A; Chen Z; Tonelli R; Pule M; Hunt L; Pession A; Shohet JM
Proc Natl Acad Sci U S A; 2005 Jan; 102(3):731-6. PubMed ID: 15644444
[TBL] [Abstract][Full Text] [Related]
12. N-Myc differentially regulates expression of MXI1 isoforms in neuroblastoma.
Armstrong MB; Mody RJ; Ellis DC; Hill AB; Erichsen DA; Wechsler DS
Neoplasia; 2013 Dec; 15(12):1363-70. PubMed ID: 24403858
[TBL] [Abstract][Full Text] [Related]
13. Pilot study to evaluate MYCN expression as a neuroblastoma cell marker to detect minimal residual disease by RT-PCR.
Wagner LM; Burger RA; Guichard SM; Raimondi SC; Santana VM; Furman WL; Barnette P; Danks MK
J Pediatr Hematol Oncol; 2006 Oct; 28(10):635-41. PubMed ID: 17023822
[TBL] [Abstract][Full Text] [Related]
14. Expression and DNA-binding activity of MYCN/Max and Mnt/Max during induced differentiation of human neuroblastoma cells.
Smith AG; Popov N; Imreh M; Axelson H; Henriksson M
J Cell Biochem; 2004 Aug; 92(6):1282-95. PubMed ID: 15258910
[TBL] [Abstract][Full Text] [Related]
15. Genome-wide analysis of gene expression associated with MYCN in human neuroblastoma.
Alaminos M; Mora J; Cheung NK; Smith A; Qin J; Chen L; Gerald WL
Cancer Res; 2003 Aug; 63(15):4538-46. PubMed ID: 12907629
[TBL] [Abstract][Full Text] [Related]
16. Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma.
Song L; Ara T; Wu HW; Woo CW; Reynolds CP; Seeger RC; DeClerck YA; Thiele CJ; Sposto R; Metelitsa LS
J Clin Invest; 2007 Sep; 117(9):2702-12. PubMed ID: 17710228
[TBL] [Abstract][Full Text] [Related]
17. WP744 is a novel anthracycline with enhanced activity against neuroblastoma.
Inge TH; Harris NL; Wu J; Azizkhan RG; Priebe W
J Surg Res; 2004 Oct; 121(2):187-96. PubMed ID: 15501458
[TBL] [Abstract][Full Text] [Related]
18. In vivo angiogenic activity of neuroblastoma correlates with MYCN oncogene overexpression.
Ribatti D; Raffaghello L; Pastorino F; Nico B; Brignole C; Vacca A; Ponzoni M
Int J Cancer; 2002 Dec; 102(4):351-4. PubMed ID: 12402304
[TBL] [Abstract][Full Text] [Related]
19. Cellular retinoic acid-binding protein II is a direct transcriptional target of MycN in neuroblastoma.
Gupta A; Williams BR; Hanash SM; Rawwas J
Cancer Res; 2006 Aug; 66(16):8100-8. PubMed ID: 16912187
[TBL] [Abstract][Full Text] [Related]
20. Aryl hydrocarbon receptor downregulates MYCN expression and promotes cell differentiation of neuroblastoma.
Wu PY; Liao YF; Juan HF; Huang HC; Wang BJ; Lu YL; Yu IS; Shih YY; Jeng YM; Hsu WM; Lee H
PLoS One; 2014; 9(2):e88795. PubMed ID: 24586395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]